Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study
Publication date: November 2026 Source: JTO Clinical and Research Reports, Volume 7, Issue 11 Author(s): Jinyong Kim, Sehhoon Park, Gyeong-Won Lee, Il-Hwan Kim, Dong-Wan Kim, Yun-Gyoo Lee, Jang Ho Cho, Eun-Kyung Cho, Hyun Woo Lee, Ji-Hyun Park, Eun Joo Kang, Youngjoo Lee, Nak-Hoon Son, So Hyeon Gwon, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study. // JTO Clinical and Research Reports. – URL: https://www.sciencedirect.com/science/article/pii/S2666364326001153?dgcid=rss_sd_all
Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study. JTO Clinical and Research Reports. https://www.sciencedirect.com/science/article/pii/S2666364326001153?dgcid=rss_sd_all
“Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study.” JTO Clinical and Research Reports.
@article{article56910,
title = {Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study},
journal = {JTO Clinical and Research Reports},
url = {https://www.sciencedirect.com/science/article/pii/S2666364326001153?dgcid=rss_sd_all}
}